Loomis, Sayles & Company
BCYC

Loomis, Sayles & Company’s Bicycle Therapeutics BCYC Stock Holding History

Loomis, Sayles & Company’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-643,775
Closed -$28.2M – 977
2022
Q1 		$28.2M Buy
643,775
+73,728
+13% +$3.44M 0.04% 238
2021
Q4 		$34.7M Buy
+570,047
New +$31.5M 0.04% 233

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Loomis, Sayles & Company's BCYC Position: Q2 2022 in Review

Loomis, Sayles & Company sold out of Bicycle Therapeutics (BCYC) in Q2 2022, closing a stake of 643,775 shares — an estimated $28.2M sold.

Loomis, Sayles & Company first reported a position in BCYC in Q4 2021 and held it in 2 quarters. The position peaked at $34.7M in Q4 2021. 81 funds tracked by Wall St. Rank hold BCYC as of Q2 2022.

  • Loomis, Sayles & Company reported no remaining Bicycle Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 643,775 Bicycle Therapeutics shares in Q2 2022, an estimated $28.2M.
  • Loomis, Sayles & Company first reported a position in Bicycle Therapeutics in Q4 2021 and held it in 2 quarters.
  • Loomis, Sayles & Company's Bicycle Therapeutics position peaked at $34.7M in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2022.

Based on Loomis, Sayles & Company's 13F filing for Q2 2022, filed 5 Aug 2022.